[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 32 of about 32
1. Poderoso WL, Santana WB, Costa EF, Cipolotti R, Fakhouri R: Ectopic schistosomiasis: description of five cases involving skin, one ovarian case and one adrenal case. Rev Soc Bras Med Trop; 2008 Nov-Dec;41(6):668-71
MedlinePlus Health Information. consumer health - Ovarian Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ectopic schistosomiasis: description of five cases involving skin, one ovarian case and one adrenal case.
  • Seven cases of patients with ectopic schistosomiasis from the State of Sergipe, Brazil, are presented (five involving skin, one ovarian and one adrenal).
  • In the dermatological cases, full cures were achieved after treatment with oxamniquine.
  • In the ovarian case, there was an association with embryonic carcinoma: this patient underwent surgery with adjuvant chemotherapy and praziquantel treatment, with satisfactory evolution.
  • The adrenal case was associated with adenoma.
  • [MeSH-major] Adrenal Cortex Diseases / parasitology. Ovarian Diseases / parasitology. Schistosoma mansoni / isolation & purification. Schistosomiasis mansoni. Skin Diseases, Parasitic / parasitology

  • Genetic Alliance. consumer health - Schistosomiasis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19142450.001).
  • [ISSN] 1678-9849
  • [Journal-full-title] Revista da Sociedade Brasileira de Medicina Tropical
  • [ISO-abbreviation] Rev. Soc. Bras. Med. Trop.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


2. Erem C, Yucel Y, Ya Z, Reis A, Kocak M, Hacihasanoglu A: Leukocytoclastic vasculitis: a rare manifestation of propylthiouracil hypersensitivity. Med Princ Pract; 2005 Sep-Oct;14(5):366-9
Hazardous Substances Data Bank. METHIMAZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CLINICAL PRESENTATION AND INTERVENTION: A 66-year-old woman with a history of a toxic adenoma was referred for evaluation of a purpuric rash on the legs and buttocks bilaterally.
  • Biopsy of the skin lesions revealed leukocytoclastic vasculitis.
  • Propylthiouracil therapy was discontinued, and methimazole started.
  • The purpuric rash resolved and surgical treatment for toxic adenoma resulted in euthyroid state.
  • [MeSH-minor] Adenoma / complications. Adenoma / drug therapy. Aged. Diagnosis, Differential. Female. Goiter, Nodular / complications. Goiter, Nodular / drug therapy. Humans. Hyperthyroidism / complications. Hyperthyroidism / drug therapy. Methimazole / therapeutic use

  • Genetic Alliance. consumer health - Hypersensitivity Vasculitis.
  • Genetic Alliance. consumer health - Vasculitis.
  • MedlinePlus Health Information. consumer health - Rashes.
  • Hazardous Substances Data Bank. PROPYL THIOURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16103706.001).
  • [ISSN] 1011-7571
  • [Journal-full-title] Medical principles and practice : international journal of the Kuwait University, Health Science Centre
  • [ISO-abbreviation] Med Princ Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antithyroid Agents; 554Z48XN5E / Methimazole; 721M9407IY / Propylthiouracil
  •  go-up   go-down


3. Anisya-Vasanth AV, Satishchandra P, Nagaraja D, Swamy HS, Jayakumar PN: Spectrum of epilepsy in tuberous sclerosis. Neurol India; 2004 Jun;52(2):210-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tuberous sclerosis (TS) is an autosomal dominant disease that affects the brain, skin, eye, heart and kidney.
  • Patients often had more than one seizure type.
  • Cutaneous manifestations were facial angiofibroma i.e. adenoma sebaceum (20), shagreen patches (7), hypopigmented macules (6), ash leaf spots (4), café-au-lait spots (2), facial hypoplasia (2) and periungual fibromas (1).
  • Most patients were on combinations of anti-convulsants and response to therapy was usually not very satisfactory.
  • [MeSH-minor] Adolescent. Anticonvulsants / therapeutic use. Child. Child, Preschool. Drug Therapy, Combination. Female. Humans. Infant. Male. Mental Disorders / etiology. Skin Diseases / etiology. Vigabatrin / therapeutic use


Advertisement
4. Olubunmi OA: Misdiagnosis of tuberous sclerosis in a Nigerian girl: a case report and review of literature. Ann Afr Med; 2010 Apr-Jun;9(2):95-101
Hazardous Substances Data Bank. VALPROIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tuberous sclerosis is a rare neuro-cutaneous syndrome, one of the phakomatosis, characterized by facial angiofibromas (adenoma sebaceum), mental retardation and epilepsy.
  • [MeSH-minor] Adolescent. Angiofibroma / diagnosis. Anticonvulsants / therapeutic use. Diagnostic Errors. Epilepsy / drug therapy. Epilepsy / etiology. Female. Humans. Intellectual Disability / etiology. Neurofibromatoses / diagnosis. Skin Neoplasms / diagnosis. Tomography, X-Ray Computed. Treatment Outcome. Valproic Acid / therapeutic use

  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • MedlinePlus Health Information. consumer health - Tuberous Sclerosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20587932.001).
  • [ISSN] 0975-5764
  • [Journal-full-title] Annals of African medicine
  • [ISO-abbreviation] Ann Afr Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Nigeria
  • [Chemical-registry-number] 0 / Anticonvulsants; 614OI1Z5WI / Valproic Acid
  •  go-up   go-down


5. Souvatzidis P, Sbano P, Mandato F, Fimiani M, Castelli A: Malignant nodular hidradenoma of the skin: report of seven cases. J Eur Acad Dermatol Venereol; 2008 May;22(5):549-54
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for nodular hidradenoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant nodular hidradenoma of the skin: report of seven cases.
  • BACKGROUND: Malignant nodular hidradenoma (MNH) is an infrequent, highly malignant, primary skin tumour derived from eccrine sweat glands.
  • The best method of treatment is still unclear: radical surgical excision is widely used, and selective lymph node dissection is also suggested.
  • The value of the adjuvant radiotherapy and chemotherapy has not been confirmed.
  • PATIENTS AND TREATMENT: Seven MNH patients (4 men, 3 women, age 60-87 years) were treated between 1991 and 2007 in the Dermatology Unit of San Donato Hospital of Arezzo and in the Section of Dermatology of University of Siena, Italy.
  • One patient underwent adjuvant radiotherapy, and three received chemotherapy.
  • Survival time was inversely proportional to the size of the tumour.
  • In our experience, radiotherapy and chemotherapy do not seem to prolong survival.
  • [MeSH-major] Adenoma, Sweat Gland / diagnosis. Skin Neoplasms / diagnosis. Sweat Gland Neoplasms / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy. Fatal Outcome. Female. Humans. Male. Middle Aged. Prognosis. Skin / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18410617.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 29
  •  go-up   go-down


6. Parlakgumus A, Yildirim S, Bolat FA, Caliskan K, Ezer A, Colakoglu T, Moray G: Dermatoses of the nipple. Can J Surg; 2009 Apr;52(2):160-1
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenoma / diagnosis. Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Epidermal Cyst / diagnosis. Epidermal Cyst / surgery. Female. Fibroma / diagnosis. Fibroma / surgery. Humans. Molluscum Contagiosum / diagnosis. Molluscum Contagiosum / drug therapy. Nevus, Blue / diagnosis. Nevus, Blue / surgery. Paget's Disease, Mammary / diagnosis. Retrospective Studies. Skin Neoplasms / diagnosis. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast J. 2001 Jul-Aug;7(4):263-5 [11678805.001]
  • [Cites] Cancer. 2006 Oct 1;107(7):1448-58 [16933329.001]
  • [Cites] Cancer. 1981 Aug 1;48(3):825-9 [6265059.001]
  • [Cites] Cancer. 2002 Jul 1;95(1):1-7 [12115309.001]
  • (PMID = 19399214.001).
  • [ISSN] 1488-2310
  • [Journal-full-title] Canadian journal of surgery. Journal canadien de chirurgie
  • [ISO-abbreviation] Can J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  • [Other-IDs] NLM/ PMC2663493
  •  go-up   go-down


7. Igbaseimokumo U: Quantification of in vivo Photofrin uptake by human pituitary adenoma tissue. J Neurosurg; 2004 Aug;101(2):272-7
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantification of in vivo Photofrin uptake by human pituitary adenoma tissue.
  • This study was designed to quantify the preferential uptake of Photofrin by pituitary adenoma tissue for intraoperative photodynamic therapy.
  • METHODS: Eight patients (seven men) with recurrent pituitary adenomas who had undergone previous surgery and radiation therapy were recruited for a Phase I/II feasibility study of the application of photodynamic therapy to pituitary tumors.
  • At the time of the operation, pituitary adenoma tissue, muscle, fat, skin, and plasma were obtained for measurement of Photofrin content by fluorometric assay.
  • The mean Photofrin level in pituitary adenoma tissue was 6.87 ng/mg (95% confidence interval [CI] 3.99-9.75), which was significantly higher than the uptake by skeletal muscle (2.24 ng/mg, 95% CI 1.28-3.2; p = 0.008), or fat (2.54 ng/mg, 95% CI 0.66-4.42; p = 0.007).
  • Nevertheless, the mean drug concentration in pituitary adenoma tissue was not significantly different from the level in plasma (7.65 microg/ml, 95% CI 5.38-9.90; p = 0.558).
  • Skin specimens were available in four patients, and these showed a mean uptake of 2.19 ng/mg.
  • CONCLUSIONS: Photofrin is preferentially retained by pituitary adenoma tissue to levels both adequate for intraoperative photodynamic therapy and approximately 50% higher than those reported for gliomas.
  • [MeSH-major] Adenoma / metabolism. Antineoplastic Agents / pharmacokinetics. Dihematoporphyrin Ether / pharmacokinetics. Hematoporphyrin Photoradiation. Pituitary Neoplasms / metabolism
  • [MeSH-minor] Adipose Tissue / metabolism. Adult. Aged. Feasibility Studies. Fluorometry. Humans. Hypophysectomy. Injections, Intravenous. Middle Aged. Muscle, Skeletal / metabolism. Skin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15309918.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 97067-70-4 / Dihematoporphyrin Ether
  •  go-up   go-down


8. Papadopoulou M, Doula S, Kitsios K, Kaltsas T, Kosta K: A boy with McCune-Albright syndrome associated with GH secreting pituitary microadenoma. Clinical findings and response to treatment. Hormones (Athens); 2006 Jul-Sep;5(3):205-9
Hazardous Substances Data Bank. TESTOLACTONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A boy with McCune-Albright syndrome associated with GH secreting pituitary microadenoma. Clinical findings and response to treatment.
  • [MeSH-major] Adenoma / complications. Fibrous Dysplasia, Polyostotic / complications. Growth Hormone-Secreting Pituitary Adenoma / complications
  • [MeSH-minor] Child. Facial Bones / radionuclide imaging. Glucagon / blood. Glucose Tolerance Test. Gonadotropin-Releasing Hormone / blood. Humans. Male. Puberty, Precocious / diagnosis. Puberty, Precocious / drug therapy. Skin Pigmentation. Somatostatin / analogs & derivatives. Somatostatin / therapeutic use. Testolactone / therapeutic use

  • Genetic Alliance. consumer health - McCune Albright syndrome.
  • Hazardous Substances Data Bank. GLUCAGON .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16950755.001).
  • [ISSN] 1109-3099
  • [Journal-full-title] Hormones (Athens, Greece)
  • [ISO-abbreviation] Hormones (Athens)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 33515-09-2 / Gonadotropin-Releasing Hormone; 51110-01-1 / Somatostatin; 6J9BLA949Q / Testolactone; 9007-92-5 / Glucagon
  •  go-up   go-down


9. Barabash R, Moreno-Suárez FG, Rodríguez L, Molina AM, Conejo-Mir J: [Nelson syndrome: a rare cause of generalized hyperpigmentation of the skin]. Actas Dermosifiliogr; 2010 Jan-Feb;101(1):76-80
Hazardous Substances Data Bank. LEVOTHYROXINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Nelson syndrome: a rare cause of generalized hyperpigmentation of the skin].
  • Its clinical manifestations are due to excessive secretion of adrenocorticotropic hormone from a pituitary adenoma, which develops after bilateral therapeutic adrenalectomy.
  • [MeSH-major] Adenoma / etiology. Adrenalectomy / adverse effects. Nelson Syndrome / etiology
  • [MeSH-minor] Adult. Combined Modality Therapy. Dicarboxylic Acids / therapeutic use. Ergolines / therapeutic use. Female. Hormone Replacement Therapy. Humans. Hydrocortisone / therapeutic use. Hypophysectomy. Neoplasms, Multiple Primary. Peptides, Cyclic / therapeutic use. Pituitary ACTH Hypersecretion / drug therapy. Pituitary ACTH Hypersecretion / etiology. Pituitary ACTH Hypersecretion / surgery. Pituitary Apoplexy / complications. Pituitary Apoplexy / surgery. Pituitary Neoplasms / complications. Pituitary Neoplasms / surgery. Radiosurgery. Somatostatin / analogs & derivatives. Somatostatin / therapeutic use. Thyroxine / therapeutic use

  • Genetic Alliance. consumer health - Nelson syndrome.
  • Hazardous Substances Data Bank. 1,7-HEPTANEDICARBOXYLIC ACID .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20109395.001).
  • [ISSN] 1578-2190
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Dicarboxylic Acids; 0 / Ergolines; 0 / Peptides, Cyclic; 118992-92-0 / lanreotide; 51110-01-1 / Somatostatin; F2VW3D43YT / azelaic acid; LL60K9J05T / cabergoline; Q51BO43MG4 / Thyroxine; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


10. Mauz PS, Maassen MM, Braun B, Brosch S: How safe is percutaneous ethanol injection for treatment of thyroid nodule? Report of a case of severe toxic necrosis of the larynx and adjacent skin. Acta Otolaryngol; 2004 Dec;124(10):1226-30
Hazardous Substances Data Bank. ETHANOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How safe is percutaneous ethanol injection for treatment of thyroid nodule? Report of a case of severe toxic necrosis of the larynx and adjacent skin.
  • OBJECTIVE: Since 1990, percutaneous ethanol injection therapy (PEIT) has been clinically applied as a treatment for autonomous functioning nodules of the thyroid as well as for cystic lesions.
  • Since its inception, PEIT has generally been regarded as an effective, low-risk, inexpensive procedure which can be performed on an ambulatory basis.
  • A cyst which developed in the right false vocal fold was removed by microsurgery 10 months later.
  • CONCLUSION: PEIT for functional thyroid gland autonomy is an inexpensive method of treating hyperthyroidism with focal autonomy on an ambulatory basis if surgical intervention and radioiodine therapy are not feasible either for medical reasons or because of refusal by the patient.
  • [MeSH-major] Adenoma / therapy. Aphonia / chemically induced. Ethanol / administration & dosage. Ethanol / adverse effects. Larynx / pathology. Skin / pathology. Thyroid Neoplasms / therapy
  • [MeSH-minor] Adult. Humans. Injections. Male. Necrosis. Vocal Cords / drug effects. Vocal Cords / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15768823.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 3K9958V90M / Ethanol
  •  go-up   go-down


11. Whatley WS, Thompson JW, Rao B: Salivary gland tumors in survivors of childhood cancer. Otolaryngol Head Neck Surg; 2006 Mar;134(3):385-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common second malignancies are acute leukemia, bone and soft tissue tumors, and carcinoma of the skin, breast, and thyroid.
  • RESULTS: Twelve survivors of childhood cancer developed a salivary gland neoplasm after completion of treatment.
  • These patients were initially treated for a variety of childhood cancers with a combination of radiation and chemotherapy.
  • The pathology of the salivary gland tumors were mucoepidermoid carcinoma (10), adenoid cystic carcinoma (1) , and pleomorphic adenoma (1).
  • CONCLUSION: Radiation and chemotherapy used to treat patients with childhood malignancies increases the risk of developing a second neoplasm of salivary gland origin.
  • The treatment of these tumors includes surgical excision of the primary, with neck dissection in patients with clinical evidence of nodal metastasis, and postoperative radiation added for pathologies with adverse features.
  • [MeSH-minor] Adenoma, Pleomorphic / diagnosis. Adenoma, Pleomorphic / surgery. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Adenoid Cystic / surgery. Carcinoma, Mucoepidermoid / diagnosis. Carcinoma, Mucoepidermoid / surgery. Child. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lung Neoplasms / secondary. Lymphatic Metastasis / diagnosis. Male. Neck Dissection. Neoplasms / drug therapy. Neoplasms / radiotherapy. Radiotherapy, Adjuvant. Registries. Retrospective Studies. Risk Factors


12. Gauerke S, Driscoll JJ: Hidradenocarcinomas: a brief review and future directions. Arch Pathol Lab Med; 2010 May;134(5):781-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hidradenocarcinomas are rare, aggressive skin adnexal tumors of sweat gland origin that demonstrate a high potential for local recurrence, metastasis, and poor outcome.
  • Currently, molecular markers of pathogenesis as well as effective forms of adjuvant chemotherapy are lacking.
  • Future studies are required to identify the histopathologic and immunohistochemical features, which may facilitate diagnosis and foster development of molecularly targeted forms of adjuvant therapy.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma, Sweat Gland / pathology. Sweat Gland Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Diagnosis, Differential. Humans. Neoplasms, Adnexal and Skin Appendage / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20441512.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 21
  •  go-up   go-down


13. Gentschev I, Stritzker J, Hofmann E, Weibel S, Yu YA, Chen N, Zhang Q, Bullerdiek J, Nolte I, Szalay AA: Use of an oncolytic vaccinia virus for the treatment of canine breast cancer in nude mice: preclinical development of a therapeutic agent. Cancer Gene Ther; 2009 Apr;16(4):320-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of an oncolytic vaccinia virus for the treatment of canine breast cancer in nude mice: preclinical development of a therapeutic agent.
  • Mammary cancers together with cancers of the skin account for about 60% of the total cancers occurring in dogs.
  • The veterinary options for therapeutic management of canine mammary cancer are limited and prognosis for such patients is poor.
  • In this study, we analyzed the functionality of the oncolytic vaccinia virus strain GLV-1h68 as a possible therapeutic agent for canine mammary cancer.
  • Cell culture data demonstrated that GLV-1h68 efficiently infected and destroyed cells of the canine mammary adenoma cell line ZMTH3.
  • This is the first report demonstrating that vaccinia virus is an effective tool for the therapy of canine mammary cancers, which might next be applied to dogs with breast tumors.
  • [MeSH-major] Adenoma / therapy. Adenoma / veterinary. Mammary Neoplasms, Animal / therapy. Oncolytic Virotherapy / methods. Vaccinia virus / physiology
  • [MeSH-minor] Animals. Antibodies, Viral / blood. Apoptosis / drug effects. Cell Line, Tumor. Dogs. Female. Haplorhini. Mice. Mice, Nude. Oncolytic Viruses / physiology. Virus Replication. Xenograft Model Antitumor Assays

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18949014.001).
  • [ISSN] 1476-5500
  • [Journal-full-title] Cancer gene therapy
  • [ISO-abbreviation] Cancer Gene Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Viral
  •  go-up   go-down


14. Eckardt A, Kuettner C: Treatment of gustatory sweating (Frey's syndrome) with botulinum toxin A. Head Neck; 2003 Aug;25(8):624-8
MedlinePlus Health Information. consumer health - Botox.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of gustatory sweating (Frey's syndrome) with botulinum toxin A.
  • Injection of botulinum toxin A has been reported as a safe and effective treatment option for patients with Frey's syndrome.
  • PATIENTS AND METHODS: A total of 69 patients who had undergone superficial parotidectomy because of adenoma were evaluated with respect to the incidence of Frey's syndrome and treatment interest.
  • Minor's iodine starch test was used to detect the affected skin area.
  • Affected skin areas were documented using a digital camera; skin areas were evaluated morphometrically.
  • A single injection of Botox per 1 cm(2) skin field was administered to those patients interested in treatment.
  • RESULTS: Of 43 patients (62%) with gustatory sweating, 33 patients requested treatment.
  • The affected skin area varied from 16 cm(2) to 81 cm(2).
  • Treatment was well tolerated with no side effects.
  • CONCLUSION: Botox A injection is a safe and effective treatment with long-lasting effects for patients with extensive gustatory sweating.
  • [MeSH-major] Botulinum Toxins, Type A / therapeutic use. Neuromuscular Agents / therapeutic use. Sweating, Gustatory / drug therapy
  • [MeSH-minor] Adenoma / surgery. Adolescent. Adult. Aged. Aged, 80 and over. Dose-Response Relationship, Drug. Female. Humans. Injections, Subcutaneous. Male. Middle Aged. Parotid Neoplasms / surgery. Postoperative Complications. Recurrence. Surveys and Questionnaires. Treatment Outcome

  • Genetic Alliance. consumer health - Frey's Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley Periodicals, Inc.
  • (PMID = 12884344.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neuromuscular Agents; EC 3.4.24.69 / Botulinum Toxins, Type A
  •  go-up   go-down


15. Mauz PS, Stiegler M, Holderried M, Brosch S: Complications of ultrasound guided percutaneous ethanol injection therapy of the thyroid and parathyroid glands. Ultraschall Med; 2005 Apr;26(2):142-5
Hazardous Substances Data Bank. ETHANOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complications of ultrasound guided percutaneous ethanol injection therapy of the thyroid and parathyroid glands.
  • OBJECTIVES: Since 1990 percutaneous ethanol injection therapy (PEIT) has been applied clinically as a treatment strategy for focal and diffuse autonomy of the thyroid, for cystic lesions and for ablation of parathyroid hyperplasia (PEA).
  • Since its inception PEIT and PEA have been regarded as an effective, inexpensive and low risk procedure.
  • MATERIAL AND METHODS: We discuss mild and severe complications of these methods reported in literature and the first case so far of a severe ethyl toxic necrosis of the larynx and adjacent skin in a patient treated with PEIT by a radiologist.
  • RESULTS: To date, no serious side effects have been reported in connection with these therapies.
  • These are the methods of choice if surgical intervention or radioiodine therapies are not practicable out of medical reasons or by refusal of the patient.
  • [MeSH-major] Adenoma / ultrasonography. Ethanol / therapeutic use. Injections, Jet / methods. Parathyroid Diseases / ultrasonography. Skin / ultrastructure. Thyroid Neoplasms / ultrasonography
  • [MeSH-minor] Humans. Hyperplasia. Treatment Outcome. Voice Disorders / drug therapy. Voice Disorders / etiology. Voice Disorders / ultrasonography

  • MedlinePlus Health Information. consumer health - Parathyroid Disorders.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15852178.001).
  • [ISSN] 0172-4614
  • [Journal-full-title] Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  • [ISO-abbreviation] Ultraschall Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 3K9958V90M / Ethanol
  •  go-up   go-down


16. Casulari LA, Naves LA, Mello PA, Pereira Neto A, Papadia C: Nelson's syndrome: complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment. Horm Res; 2004;62(6):300-5
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nelson's syndrome: complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment.
  • Thereafter, she used hydrocortisone acetate replacement therapy (35.5 mg divided into two daily doses).
  • At the age of 26 years, the patient exhibited the clinical signs of the Nelson's syndrome, i.e. skin and gingival hyperpigmentation accompanied by amenorrhea, and elevated ACTH plasma levels (2,850 pg/ml, normal range 15-80 pg/ml).
  • Due to sleepiness and weight gain, the cyproheptadine treatment was interrupted and substituted by a cabergoline (0.5 mg twice a week) therapy.
  • The MRI analysis of the sella region demonstrated a complete remission of the pituitary adenoma.
  • The results obtained show for the first time that a long-term treatment with cabergoline also brings about a complete remission of Nelson's syndrome in the presence of a pituitary macroadenoma.
  • [MeSH-major] Cyproheptadine / therapeutic use. Dopamine Agonists / therapeutic use. Ergolines / therapeutic use. Nelson Syndrome / drug therapy
  • [MeSH-minor] Adenoma / complications. Adenoma / pathology. Adenoma / surgery. Adrenalectomy. Adrenocorticotropic Hormone / blood. Adult. Bromocriptine / therapeutic use. Female. Hormone Replacement Therapy. Humans. Magnetic Resonance Imaging. Pituitary Neoplasms / complications. Pituitary Neoplasms / pathology. Pituitary Neoplasms / surgery

  • Hazardous Substances Data Bank. CYPROHEPTADINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15557761.001).
  • [ISSN] 0301-0163
  • [Journal-full-title] Hormone research
  • [ISO-abbreviation] Horm. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Dopamine Agonists; 0 / Ergolines; 2YHB6175DO / Cyproheptadine; 3A64E3G5ZO / Bromocriptine; 9002-60-2 / Adrenocorticotropic Hormone; LL60K9J05T / cabergoline
  •  go-up   go-down


17. Akintoye SO, Chebli C, Booher S, Feuillan P, Kushner H, Leroith D, Cherman N, Bianco P, Wientroub S, Robey PG, Collins MT: Characterization of gsp-mediated growth hormone excess in the context of McCune-Albright syndrome. J Clin Endocrinol Metab; 2002 Nov;87(11):5104-12
SciCrunch. Clinical Genomic Database: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • McCune-Albright syndrome (MAS) is a disorder characterized by the triad of café-au-lait skin pigmentation, polyostotic fibrous dysplasia of bone, and hyperfunctioning endocrinopathies, including GH excess.
  • The aim of this study was to estimate the prevalence of GH excess in MAS, characterize the clinical and endocrine manifestations, and describe the response to treatment.
  • Pituitary adenoma was detected in 4 of 12 (33%) patients.
  • GH excess is common in MAS and results in a distinct clinical phenotype characterized by inappropriately normal stature, TRH responsiveness, prolactin cosecretion, small or absent pituitary tumors, a consistent but inadequate response to treatment with cabergoline, and an intermediate response to LAO.
  • [MeSH-minor] Adenoma / complications. Adenoma / diagnosis. Adenoma / drug therapy. Antineoplastic Agents / therapeutic use. Body Height. DNA Mutational Analysis. Ergolines / therapeutic use. Insulin-Like Growth Factor I / analysis. Magnetic Resonance Imaging. Octreotide / therapeutic use. Pituitary Neoplasms / complications. Pituitary Neoplasms / diagnosis. Pituitary Neoplasms / drug therapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12414879.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Grant] Italy / Telethon / / E.1029
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Ergolines; 12629-01-5 / Human Growth Hormone; 67763-96-6 / Insulin-Like Growth Factor I; EC 3.6.5.1 / GTP-Binding Protein alpha Subunits, Gs; LL60K9J05T / cabergoline; RWM8CCW8GP / Octreotide
  •  go-up   go-down


18. Bollée G, Patey N, Cazajous G, Robert C, Goujon JM, Fakhouri F, Bruneval P, Noël LH, Knebelmann B: Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. Nephrol Dial Transplant; 2009 Feb;24(2):682-5
MedlinePlus Health Information. consumer health - Blood Clots.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Drugs targeting the VEGF pathway are associated with renal adverse events, including proteinuria, hypertension and thrombotic microangiopathy (TMA).
  • A 44-year-old woman with a history of malignant skin hidradenoma was started on sunitinib for refractory disease.
  • She developed hypertension after 2 weeks and low-grade proteinuria after 4 weeks.
  • This suggests that all anti-VEGF drugs may share a common risk for developing renal adverse events, including TMA.
  • The renin-angiotensin system blockers may be considered in patients with mild clinical manifestations and in the absence of therapeutic alternative to anti-VEGF drugs.
  • [MeSH-major] Indoles / adverse effects. Kidney / blood supply. Kidney / drug effects. Pyrroles / adverse effects. Thrombosis / chemically induced. Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • [MeSH-minor] Adenoma, Sweat Gland / drug therapy. Adult. Antineoplastic Agents / adverse effects. Female. Humans. Protein Kinase Inhibitors / adverse effects. Skin Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nephrol Dial Transplant. 2009 Jun;24(6):2002-3 [19332867.001]
  • (PMID = 19054798.001).
  • [ISSN] 1460-2385
  • [Journal-full-title] Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • [ISO-abbreviation] Nephrol. Dial. Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Indoles; 0 / Protein Kinase Inhibitors; 0 / Pyrroles; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 0 / sunitinib
  •  go-up   go-down


19. Graefe T, Wollina U, Schulz H, Burgdorf W: Muir-Torre syndrome - treatment with isotretinoin and interferon alpha-2a can prevent tumour development. Dermatology; 2000;200(4):331-3
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Muir-Torre syndrome - treatment with isotretinoin and interferon alpha-2a can prevent tumour development.
  • A 57-year-old man presented with multiple sebaceous tumours, kerato-acanthomas, verrucous carcinoma of the nose, renal cell and transitional cell carcinomas of the left kidney, adenoma of the colon and a positive family history of colon carcinoma.
  • 3 x 10(6) U three times a week along with 50 mg isotretinoin daily as well as topical isotretinoin gel.
  • During a follow-up of 29 months, only 1 sebaceous skin tumour developed and was removed, whereas more than 30 such skin tumours had been surgically removed during the last 3 years.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms, Multiple Primary / drug therapy. Sebaceous Gland Neoplasms / drug therapy
  • [MeSH-minor] Humans. Interferon-alpha / administration & dosage. Isotretinoin / administration & dosage. Male. Middle Aged. Recombinant Proteins. Skin / drug effects. Skin / pathology. Syndrome

  • Genetic Alliance. consumer health - Keratoacanthoma.
  • Hazardous Substances Data Bank. 13-CIS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 S. Karger AG, Basel
  • (PMID = 10894967.001).
  • [ISSN] 1018-8665
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Recombinant Proteins; 47RRR83SK7 / interferon alfa-2a; EH28UP18IF / Isotretinoin
  •  go-up   go-down


20. Trepp R, Padberg BC, Varga Z, Cathomas R, Inauen R, Reinhart WH: Extensive extranodal metastases of basal-like breast cancer with predominant myoepithelial spindle cell differentiation. Pathol Res Pract; 2010 May 15;206(5):334-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A differentiation towards myoepithelial cells has been demonstrated in several types of lesions in the breast.
  • These include multifocal myoepitheliomatosis, the rare mixed tumor or pleomorphic adenoma, adenoid cystic carcinoma, adenomyoepithelioma and myoepithelial carcinoma (malignant myoepithelioma).
  • Despite an extensive chemotherapy and radiotherapy, the tumor was rapidly progressive, forming a finally exulcerating local tumor relapse and widespread metastases to the myocardium, lungs, liver, kidneys and skin.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma / secondary. Kidney Neoplasms / secondary. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Skin Neoplasms / secondary


21. Chase DM, Basu T, Saffari B, Ries S, Berman ML: Malignant eccrine spiradenoma of the vulva: a case report and review of the literature. Int J Gynecol Cancer; 2006 May-Jun;16(3):1465-9
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant eccrine spiradenoma is a rare skin tumor of sweat gland origin.
  • As malignant eccrine spiradenoma is a rare tumor, no standard care exists for treatment and postoperative management.
  • Based on our review of the literature, wide local excision appears to be the preferred initial treatment.
  • Furthermore, adjuvant chemotherapy and/or radiation does not seem to improve survival in patients with advanced or recurrent cancer.
  • Although lymph node sampling and/or lymphadenectomy is frequently reported in the treatment of this tumor, hematogenous metastasis can also occur.
  • [MeSH-minor] Adenoma, Sweat Gland / diagnosis. Adult. Female. Humans. Neoplasm Recurrence, Local / prevention & control. Sentinel Lymph Node Biopsy / methods

  • Genetic Alliance. consumer health - Malignant eccrine spiradenoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16803551.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 13
  •  go-up   go-down


22. Scott RH, Mansour S, Pritchard-Jones K, Kumar D, MacSweeney F, Rahman N: Medulloblastoma, acute myelocytic leukemia and colonic carcinomas in a child with biallelic MSH6 mutations. Nat Clin Pract Oncol; 2007 Feb;4(2):130-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At the age of 7 years she had widespread hyperpigmented and hypopigmented skin lesions, and had developed medulloblastoma, which was treated with chemotherapy and craniospinal irradiation.
  • At the age of 10 years she had developed acute myelocytic leukemia, M5.
  • She was treated with chemotherapy including sibling bone marrow transplant with busulfan/cyclophosphamide conditioning.
  • Investigations Immunohistochemical analysis was performed on a sample of colonic adenoma.
  • It is important to consider this diagnosis in children presenting with malignancy and abnormal skin pigmentation, even in the absence of a strong family history of tumors.


23. Selesnick SH, Burt BM: Regional spread of nonneurogenic tumors to the skull base via the facial nerve. Otol Neurotol; 2003 Mar;24(2):326-33
Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Five patients received adjuvant radiation, and two received adjuvant radiation and chemotherapy.
  • RESULTS: Five cases of malignancy were reported: one case of parotid adenoid cystic carcinoma, one case of parotid mucoepidermoid carcinoma, two cases of squamous cell carcinoma of the skin, and one case of an unidentified carcinoma.
  • In addition, one case of benign pleomorphic adenoma of the parotid gland that circumferentially involved an intratemporal segment of the facial nerve was reported.
  • Four patients had unresectable malignant disease, and two died despite multimodality therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12621352.001).
  • [ISSN] 1531-7129
  • [Journal-full-title] Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
  • [ISO-abbreviation] Otol. Neurotol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; AU0V1LM3JT / Gadolinium
  •  go-up   go-down


24. Marks PV, Belchetz PE, Saxena A, Igbaseimokumo U, Thomson S, Nelson M, Stringer MR, Holroyd JA, Brown SB: Effect of photodynamic therapy on recurrent pituitary adenomas: clinical phase I/II trial--an early report. Br J Neurosurg; 2000 Aug;14(4):317-25
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of photodynamic therapy on recurrent pituitary adenomas: clinical phase I/II trial--an early report.
  • Radiotherapy has been employed as an adjuvant therapy to address residual disease with favourable results.
  • We are therefore investigating the effectiveness of photodynamic therapy (PDT) on recurrent pituitary adenomas in humans.
  • One patient developed severe skin photosensitization due to early exposure to direct sunlight and three others displayed minor skin reactions.
  • There was no treatment-related mortality or morbidity.
  • One patient (operated transcranially) developed hemiparesis postoperatively, which recovered completely.
  • We think this is unrelated to the treatment.
  • This prospective study demonstrates that PDT may be safely applied to the pituitary fossa by the trans-sphenoidal route and indicates the need for a randomized, controlled trial in order to establish its therapeutic potential.
  • [MeSH-major] Adenoma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Photochemotherapy / methods. Pituitary Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Pilot Projects

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11045196.001).
  • [ISSN] 0268-8697
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  •  go-up   go-down


25. Tóth M, Töke J, Kiss E, Bernád I, Miheller P, Szücs N, Rácz K: [Acromegaly associated with McCune-Albright syndrome]. Orv Hetil; 2002 May 12;143(19 Suppl):1070-3
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • McCune-Albright syndrome is characterized by polyostotic fibrous dysplasia, cafe au lait pigmentation of the skin, and multiple endocrinopathies.
  • After an unsuccessful therapy with bromocriptine lasting three months, long-acting octreotide (Sandostatin LAR, Novartis) treatment was started.
  • After a 12-months course of treatment, serum growth hormone levels markedly decreased, clinical symptoms improved, but serum insulin-like growth factor I levels remained unchanged.
  • These observations that serum insulin-like growth factor I levels failed to reflect the decrease of serum growth hormone concentrations after long-acting octreotide treatment suggest that the increased production of insulin-like growth factor I in patients with acromegaly due to McCune-Albright syndrome may involve mechanism(s) other than increased growth hormone levels.
  • [MeSH-major] Acromegaly / drug therapy. Acromegaly / etiology. Antineoplastic Agents / therapeutic use. Fibrous Dysplasia, Polyostotic / complications. Fibrous Dysplasia, Polyostotic / drug therapy. Octreotide / therapeutic use
  • [MeSH-minor] Adenoma / blood. Adenoma / complications. Adult. Delayed-Action Preparations. Hormones / therapeutic use. Human Growth Hormone / blood. Humans. Insulin-Like Growth Factor I / metabolism. Male. Pituitary Neoplasms / blood. Pituitary Neoplasms / complications. Treatment Outcome. Treatment Refusal

  • Genetic Alliance. consumer health - Acromegaly.
  • Genetic Alliance. consumer health - McCune Albright syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12063863.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Delayed-Action Preparations; 0 / Hormones; 12629-01-5 / Human Growth Hormone; 67763-96-6 / Insulin-Like Growth Factor I; RWM8CCW8GP / Octreotide
  •  go-up   go-down


26. Heaney AP: PPAR-gamma in Cushing's disease. Pituitary; 2004;7(4):265-9
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor-derived ACTH leads to adrenal-derived steroid hypersecretion and results in many disabling and sometimes life-threatening symptoms including abnormal fat deposition, skin thinning, psychological disturbances, hypertension, diabetes, osteoporosis and muscle weakness.
  • Post-surgical persistence of ACTH hypersecretion may require pituitary-directed radiation, but this treatment may take some time to be effective, and like extensive surgical pituitary tumor resection, ultimately leads to partial- or total hypopituitarism in approximately 80% of cases.
  • Although hypercortisolism may be completely resolved by adrenalectomy, this procedure does not suppress, and may act as a stimulus to pituitary tumor growth, and is associated with other co-morbidity.
  • Although some currently available drug-based treatments for Cushing's disease effectively control hypercortisolism, their drawback has been that they do not impact on pituitary tumor growth.
  • Recent studies have identified the potential utility of peroxisome-proliferator activating receptor-gamma (PPAR-gamma) novel ligands in in vitro, and in vivo Cushing's disease models, and have paved the way for early clinical studies to develop novel therapeutic approaches in Cushing's disease.
  • [MeSH-major] PPAR gamma / metabolism. Pituitary ACTH Hypersecretion / drug therapy
  • [MeSH-minor] ACTH-Secreting Pituitary Adenoma / drug therapy. ACTH-Secreting Pituitary Adenoma / pathology. Adrenocorticotropic Hormone / metabolism. Cushing Syndrome / drug therapy. Cushing Syndrome / metabolism. Humans. Ligands. Neoplasm Invasiveness. Pituitary Neoplasms / drug therapy. Pituitary Neoplasms / pathology. Thiazolidinediones / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Endocrinol. 2004 Jun;150(6):863-75 [15191358.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Mar;90(3):1340-6 [15585550.001]
  • [Cites] Neuro Endocrinol Lett. 2005 Feb;26(1):51-4 [15726020.001]
  • [Cites] J Clin Invest. 2003 May;111(9):1381-8 [12727930.001]
  • [Cites] Clin Endocrinol (Oxf). 1991 Jan;34(1):63-9 [2004474.001]
  • [Cites] Diabetes. 1996 Dec;45(12):1661-9 [8922349.001]
  • [Cites] Nature. 1990 Oct 18;347(6294):645-50 [2129546.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Feb;62(2):259-61 [15670207.001]
  • [Cites] Acta Neurochir (Wien). 2001;143(5):477-81; discussion 481-2 [11482698.001]
  • [Cites] Nat Rev Cancer. 2004 Apr;4(4):285-95 [15057288.001]
  • [Cites] Nat Med. 1998 Sep;4(9):1046-52 [9734398.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Nov;84(11):3859-66 [10566620.001]
  • [Cites] Ann Intern Med. 1988 Sep 15;109(6):487-93 [2843068.001]
  • [Cites] Neuro Oncol. 2001 Jul;3(3):141-51 [11465394.001]
  • [Cites] Lancet. 1987 Mar 7;1(8532):573 [2881126.001]
  • [Cites] J Clin Endocrinol Metab. 1985 Oct;61(4):718-22 [4031015.001]
  • [Cites] Nat Med. 2002 Nov;8(11):1281-7 [12379847.001]
  • [Cites] Ann N Y Acad Sci. 2002 Sep;970:119-33 [12381547.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):526-9 [10690849.001]
  • [Cites] N Engl J Med. 1995 Mar 23;332(12):791-803 [7862184.001]
  • [Cites] Nature. 1998 Jan 1;391(6662):79-82 [9422508.001]
  • [Cites] Clin Ther. 2002 Mar;24(3):378-96 [11952022.001]
  • [Cites] Int J Epidemiol. 2000 Apr;29(2):197-207 [10817114.001]
  • [Cites] Pituitary. 2002;5(2):77-82 [12675504.001]
  • [Cites] Diabetes. 1998 Apr;47(4):507-14 [9568680.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Apr;56(4):541-51 [11966748.001]
  • [Cites] Clin Endocrinol (Oxf). 1991 Aug;35(2):169-78 [1657460.001]
  • [Cites] Nature. 1992 Aug 27;358(6389):771-4 [1324435.001]
  • [Cites] J Neurosurg. 2001 Jul;95(1):1-8 [11453376.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):1-9 [12538445.001]
  • (PMID = 16416039.001).
  • [ISSN] 1386-341X
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ligands; 0 / PPAR gamma; 0 / Thiazolidinediones; 9002-60-2 / Adrenocorticotropic Hormone; AA68LXK93C / 2,4-thiazolidinedione
  • [Number-of-references] 35
  •  go-up   go-down


27. Oudidi A, El-Alami MN, Boulaich M, Jazouli N, Kzadri M: [Primary sub-mandibular gland tumours: experience based on 68 cases]. Rev Laryngol Otol Rhinol (Bord); 2006;127(3):187-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sub-mandibulary gland tumours are less common than tumours of the parotid and pose many clinical and therapeutic challengers.
  • Clinical suspicion of malignancy was associated with symptom of pain, cervical adenopathy, nerve palsy, skin and/or bone invasion.
  • Definitive diagnosis was by complete excision and pathological examination.
  • Pleomorphic adenoma (n= 32) were the most frequent benign tumours.
  • Treatment was by total surgical excision of the submandibular gland for the begnin tumours.
  • Radiotherapy was performed in 24 cases and chemotherapy in 10 cases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17007195.001).
  • [ISSN] 0035-1334
  • [Journal-full-title] Revue de laryngologie - otologie - rhinologie
  • [ISO-abbreviation] Rev Laryngol Otol Rhinol (Bord)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


28. Kurz D, Ciulla TA: Novel approaches for retinal drug delivery. Ophthalmol Clin North Am; 2002 Sep;15(3):405-10
MedlinePlus Health Information. consumer health - Retinal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel approaches for retinal drug delivery.
  • Novel methods of ophthalmic drug delivery are being developed to facilitate treatment of a variety of eye diseases.
  • Pharmaceuticals administered intravitreally are able to bypass the blood-ocular barrier to achieve constant therapeutic levels in the eye, while minimizing systemic side effects.
  • Sustained-release intravitreal implants are being developed to enhance further the intravitreal route of administration.
  • Liposomes, microscopic vesicles with a membrane-like lipid bilayer surrounding an aqueous compartment, are being developed to incorporate a wide variety of drug molecules, proteins, nucleotides, and even plasmids giving them great potential for use in ophthalmology.
  • Conjugate drugs, which are covalently linked, decrease drug solubility, which increases their half-life and also limits the amount of active drug present at a given time.
  • Retrovirus, adenovirus, adenoma-associated virus, herpes virus, and lentivirus have been investigated for gene transfer to the retina.
  • Finally, iontophoresis, a method of drug delivery typically involving the application of low electric currents to drive molecules across barriers, such as skin, is being explored for ophthalmic applications.
  • [MeSH-major] Drug Delivery Systems. Ophthalmic Solutions / therapeutic use. Retina / drug effects. Retinal Diseases / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12434490.001).
  • [ISSN] 0896-1549
  • [Journal-full-title] Ophthalmology clinics of North America
  • [ISO-abbreviation] Ophthalmol Clin North Am
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ophthalmic Solutions
  • [Number-of-references] 67
  •  go-up   go-down


29. Shraga-Slutzky I, Shimon I, Weinshtein R: Clinical and biochemical stabilization of Nelson's syndrome with long-term low-dose cabergoline treatment. Pituitary; 2006;9(2):151-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and biochemical stabilization of Nelson's syndrome with long-term low-dose cabergoline treatment.
  • We report the results of long-term (6-year) treatment of Nelson's syndrome with the long-acting dopamine agonist, cabergoline, in a 55-year-old woman.
  • The disease presented 26 years after bilateral adrenalectomy and radiation treatment for Cushing's disease, followed by glucocorticoid and mineralocorticoid replacement therapy.
  • Signs of Nelson's syndrome included skin and mucosal hyperpigmentation accompanied by elevated plasma levels of adrenocorticotropic hormone (ACTH) (984 pmol/l; normal, 2.0-11.5 pmol/l).
  • Because of visual loss, transsphenoidal surgery was performed, with partial excision of the adenoma and chiasmal decompression, followed by radiosurgery.
  • Therefore, cabergoline treatment (1.5 mg/week) was initiated.
  • This case demonstrates that long-term cabergoline treatment may be efficient in patients with Nelson's syndrome.
  • [MeSH-major] Dopamine Agonists / therapeutic use. Ergolines / therapeutic use. Nelson Syndrome / drug therapy
  • [MeSH-minor] Dose-Response Relationship, Drug. Female. Humans. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Horm Res. 2004;62(6):300-5 [15557761.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Apr;89(4):1674-83 [15070930.001]
  • [Cites] N Engl J Med. 1994 Oct 6;331(14):904-9 [7915824.001]
  • [Cites] J Clin Endocrinol Metab. 1976 Nov;43(5):1179-82 [186479.001]
  • [Cites] Endocrinol Jpn. 1992 Aug;39(4):385-95 [1332855.001]
  • [Cites] J Clin Endocrinol Metab. 2004 May;89(5):2452-62 [15126577.001]
  • [Cites] J Endocrinol Invest. 1999 Dec;22(11):860-5 [10710275.001]
  • [Cites] Acta Endocrinol (Copenh). 1988 Nov;119(3):435-42 [2847474.001]
  • [Cites] Horm Res. 2000;53 Suppl 3:76-87 [10971110.001]
  • [Cites] Clin Endocrinol (Oxf). 1998 Oct;49(4):533-9 [9876353.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Mar;80(3):841-5 [7883840.001]
  • [Cites] Endocr Rev. 1993 Aug;14 (4):443-58 [7693447.001]
  • [Cites] Clin Endocrinol (Oxf). 2006 May;64(5):519-22 [16649970.001]
  • [Cites] J Clin Endocrinol Metab. 1989 Sep;69(3):500-9 [2760167.001]
  • [Cites] Clin Endocrinol (Oxf). 1990 Feb;32(2):193-201 [2161298.001]
  • [Cites] J Clin Endocrinol Metab. 1983 May;56(5):985-91 [6300181.001]
  • [Cites] Endocrinol Metab Clin North Am. 1999 Mar;28(1):211-22 [10207692.001]
  • [Cites] J Clin Endocrinol Metab. 1980 Aug;51(2):307-11 [6249835.001]
  • [Cites] Expert Opin Pharmacother. 2000 Mar;1(3):555-74 [11249538.001]
  • (PMID = 16845600.001).
  • [ISSN] 1386-341X
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dopamine Agonists; 0 / Ergolines; LL60K9J05T / cabergoline
  •  go-up   go-down


30. Sideras K, Menefee ME, Burton JK, Erlichman C, Bible KC, Ivy SP: Profound hair and skin hypopigmentation in an African American woman treated with the multi-targeted tyrosine kinase inhibitor pazopanib. J Clin Oncol; 2010 Jul 1;28(19):e312-3
Genetic Alliance. consumer health - Hypomelanotic disorder.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Profound hair and skin hypopigmentation in an African American woman treated with the multi-targeted tyrosine kinase inhibitor pazopanib.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20516434.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CM / N01 CM062205; United States / NCI NIH HHS / CA / CA15083; United States / NCI NIH HHS / CM / CM62205
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Sulfonamides; 7RN5DR86CK / pazopanib
  •  go-up   go-down


31. Tursen U, Pata C, Kaya TI, Dusmez D, Ikizoglu G: Generalized granuloma annulare associated with Plummer's disease. J Eur Acad Dermatol Venereol; 2002 Jul;16(4):419-20
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenoma / pathology. Granuloma Annulare / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adrenal Cortex Hormones / administration & dosage. Biopsy, Needle. Female. Follow-Up Studies. Humans. Leg Dermatoses / diagnosis. Leg Dermatoses / drug therapy. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Granuloma Annulare.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12224712.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  •  go-up   go-down


32. Meyskens FL Jr, McLaren CE: Chemoprevention, risk reduction, therapeutic prevention, or preventive therapy? J Natl Cancer Inst; 2010 Dec 15;102(24):1815-7
eScholarship, California Digital Library, University of California. Full text from University of California eScholarship .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoprevention, risk reduction, therapeutic prevention, or preventive therapy?
  • [MeSH-minor] Adenoma / prevention & control. Breast Neoplasms / prevention & control. Carcinoma, Basal Cell / prevention & control. Carcinoma, Squamous Cell / prevention & control. Celecoxib. Colorectal Neoplasms / prevention & control. Cyclooxygenase 2 Inhibitors / administration & dosage. Cyclooxygenase 2 Inhibitors / adverse effects. Disease Progression. Female. Humans. Keratosis, Actinic / drug therapy. Keratosis, Actinic / pathology. Male. Prostatic Neoplasms / prevention & control. Pyrazoles / administration & dosage. Pyrazoles / adverse effects. Randomized Controlled Trials as Topic. Skin Neoplasms / prevention & control. Sulfonamides / administration & dosage. Sulfonamides / adverse effects. Terminology as Topic

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CELECOXIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Natl Cancer Inst. 2010 Dec 15;102(24):1835-44 [21115882.001]
  • (PMID = 21115881.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA062203
  • [Publication-type] Comment; Editorial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Cyclooxygenase 2 Inhibitors; 0 / Pyrazoles; 0 / Sulfonamides; JCX84Q7J1L / Celecoxib
  •  go-up   go-down






Advertisement